Compare Moderna, Inc. (MRNA) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Shell PLC — how do they compare? Moderna, Inc. trades at $137.1 (market cap $54.14B), while Shell PLC trades at $95.97 (market cap $271.50B). The key difference: Shell PLC is far larger — about 5× Moderna, Inc.'s market cap, and Shell PLC pays a 3.27% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SHEL | |
|---|---|---|
Market Cap | $54.14B | $271.50B |
Sector | Health | Energy |
52-Week High | $174.38 | $95.60 |
52-Week Low | $22.36 | $70.31 |
Enterprise Value | $50.29B | $313.20B |
Dividend Yield | — | 3.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Shell (SHEL) trades at $95.32, up 2.55% on the day and near its record high, driven by strong crude oil prices and positive earnings momentum with recent quarterly beats. The stock shows a bullish technical outlook, supported by moving averages, while fundamentals reflect solid profitability with an 8.76% net margin and attractive valuation metrics like a P/E of 10.54. Recent developments include strategic acquisitions in deepwater projects and retail expansion, enhancing growth prospects.
The outlook for SHEL remains positive, with analyst consensus favoring a buy rating and a $101 price target, implying upside potential. Key opportunities include oil price tailwinds and operational efficiency, though risks involve revenue volatility from energy markets and geopolitical tensions, as highlighted by recent news. Investors should weigh robust cash flows against cyclical industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
